A. Korman
Immunology · 2003–2015
A researcher in the Science corpus: 10 papers; trusts 2 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 154 citations into it; #1,330 of 2,160 by trust here, #68 by citations
- Oncology — 146 citations into it; #1,079 of 1,698 by trust here, #51 by citations
Whom A. Korman trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- James P. Allison (in Immunology)
- E. Wherry (in Immunology)
Who trusts A. Korman
- D. Pardoll (in Immunology)
- James P. Allison (in Oncology)
Papers from A. Korman's perspective
Ordered by how strongly the researchers A. Korman trusts endorse each paper. Same corpus, a different order for every researcher.
- Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies (Journal of Experimental Medicine)
- Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 (Journal of Experimental Medicine)
- Cancer immunoediting: from immunosurveillance to tumor escape (Nature Immunology)
- Modulation of tryptophan catabolism by regulatory T cells (Nature Immunology)
- Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive… (Journal of Experimental Medicine)
- Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease (Nature)
- Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. (Advances in Immunology)
- Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. (Proceedings of the National Academy of Sciences of the United States of America)
- Cancer-related inflammation (Nature)
Their papers
- TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. (2015) — 694 citations
- Evolving synergistic combinations of targeted immunotherapies to combat cancer (2015) — 621 citations
- Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens (2014) — 1,894 citations
- Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients (2013) — 3,871 citations
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells (2013) — 804 citations
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012) — 7,418 citations
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010) — 2,866 citations
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies (2009) — 936 citations
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients (2008) — 675 citations
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients (2003) — 1,020 citations